Call for Late-Breaking Clinical Trials (LBCT)

As a new important forum added to this year's conference, Late-Breaking Clinical Trials (LBCT) will bring together top experts and scholars from all over the world to share the latest research results and clinical practice experience in the cardiovascular field, grasp the forefront of medical development, stimulate scientific research and innovative thinking, and continue to promote the quality development of China's cardiovascular disease clinical research. We will continue to promote the high quality of clinical research on cardiovascular diseases in China.

We are now openly soliciting the latest clinical research for all doctors and colleagues, and welcome you to visit the official website of the conference: www.qiccmd.com to submit your manuscripts!

Contents of the Call for Papers
The latest clinical studies in the field of cardiovascular disease (e.g., major studies, prospective randomised controlled trials, multicentre observational or registry studies, etc.) that satisfy the following two conditions at the same time:
1. The results of the primary endpoint or important secondary endpoints are to be presented for the first time at QICC 2024;
2. have not been published publicly prior to the QICC 2024 Congress.

Contributors of accepted clinical studies will be invited to present at the QICC 2024 Congress in the Newly Revealed Clinical Trials Forum. By submitting a clinical study to the Congress, the contributor confirms that the study is nearing completion and will be presented at the QICC Congress upon acceptance, regardless of whether the results are positive or negative.

Manuscript Submission:
In order to facilitate the submission and revision of manuscripts, as well as to be informed of the acceptance and arrangement of your manuscripts, the conference only accepts online submissions on the Internet, and does not accept email or paper submissions. Please visit the official website of the conference (http://www.qiccmd.com/2024/submission.php?cid=148) for submission requirements, procedures and details.

Deadline: 30 September 2024
Submission consultation: Shanshan Liu, 19560480875
Submission technical support: Mr. Feng, 18610065085
Email: sub@qiccmd.com